A GLP-1 Prescription Is Not a Treatment Plan

On the first of December 2025, the World Health Organization issued its first global guideline on GLP-1 therapies for obesity in adults. It contained two conditional recommendations. The first was that these medicines may be used for long term treatment of obesity in adults. The second, and the one that received far less attention, was that intensive behavioral interventions involving structured dietary and physical activity support may be offered alongside them. Conditional, based on low certainty evidence, which is how WHO phrases things when the trials have not been done rather than when the idea is doubtful.

I read that second recommendation and thought: finally, in writing.

Because from where I sit as an endocrinologist, the medication is the easiest part of this. It is the part that takes ninety seconds to prescribe and years to do properly.

What the medication does and does not do

Semaglutide, tirzepatide, and liraglutide are genuinely significant drugs. They slow gastric emptying, act on appetite regulation centers in the hypothalamus and brainstem, improve insulin secretion in a glucose dependent way, and reduce what patients describe as food noise, the constant background negotiation with eating that many people have carried since adolescence.

For a great many patients, the relief from that noise is the most meaningful part of the entire treatment. It is not a small thing to stop arguing with yourself all day.

What the medication does not do is change the conditions that produced the disease. It does not repair a sleep schedule. It does not build muscle. It does not resolve the stress physiology driving cortisol. It does not address the relationship with food that was formed at age nine, or the belief that hunger is a moral failure, or the pattern of eating at eleven at night because that is the first quiet hour of the day.

Appetite suppression can mask all of that beautifully. And masking is not the same as treating.

What happens when the medication is the whole plan

I see a predictable sequence in patients who come to me after being prescribed a GLP-1 with no structure around it.

Weight falls quickly for six to nine months. Because appetite is low and no one gave guidance on what to eat, total intake drops sharply and protein intake drops with it. Lean mass goes down along with fat mass, sometimes substantially. Strength declines. Energy declines. Resting metabolic rate declines more than the weight loss alone would predict.

Then the losses slow, as they do for everyone. At that point the patient has lost real muscle, has not built any new habits, and is facing an indefinite prescription with rising cost and no exit strategy. If the medication stops for any reason, cost, supply, insurance, side effects, appetite returns to a body that is now carrying less muscle and burning fewer calories at rest. Regain is fast and it is disproportionately fat.

If any of this sounds like your experience, you can book a virtual consultation with Dr. Sater to review your history and testing in full.

That outcome is not a failure of the drug. It is what happens when a powerful tool is used without the structure it was studied within. Every major trial that produced the results people quote included lifestyle intervention as part of the protocol.

What belongs around the prescription

Protein first, deliberately. When appetite drops by half, the food that gets eliminated is usually the food that required effort to prepare, which is almost always the protein. I set a specific gram target with every patient starting a GLP-1, and we track it early rather than after the damage shows up on a body composition scan.

Resistance training from the beginning, not later. Two to three sessions per week, progressive, focused on major movement patterns. This is the single most effective protection against lean mass loss during weight reduction, and starting it in month one is far easier than trying to recover strength in month ten.

Real behavioral work. Not a pamphlet about portion sizes. Structured attention to the patterns underneath eating, the stress states that trigger them, the sleep debt that amplifies them, and the beliefs that keep them in place. A GLP-1 buys you a stretch of time where eating differently costs less willpower than it ever has. What you build during that stretch is what you keep afterward.

Monitoring that goes beyond the scale. Body composition when available, strength benchmarks, protein intake, blood pressure, lipids, A1c, and how the person actually feels. Weight alone tells you almost nothing about whether the treatment is working well.

A conversation about the long term, held early. Obesity is a chronic condition, and chronic conditions are usually managed rather than cured. Some patients will remain on therapy indefinitely and that is a legitimate medical decision. Others will taper. Either way, that conversation belongs at the beginning, not at the point where insurance stops covering it.

The part I care about most

The WHO framed obesity care as requiring lifelong, person centered management. I would put it more plainly.

Most metabolic disease is tied to behavior, and most behavior is tied to a belief system operating below conscious awareness. Patients rarely need to be told what to eat. They usually already know. What they need is to understand why the knowing has not translated into doing, and that question has an answer worth finding.

A GLP-1 can make the physiology easier while you find it. That is a genuine gift, and it deserves to be used well.